Earnings Call · Q4 FY2021·2022-02-28

Q4 21EPS +78.26%·Rev n/aQ3 21EPS -7.69%·Rev n/aQ2 21EPS -38.10%·Rev n/aQ1 21EPS -38.10%·Rev n/a⚠ consensus missing

OCULAR THERAPEUTIX, INC OCUL

Donald Notman — Chief Financial Officer

Antony Mattessich — Chief Executive Officer

Michael Goldstein — Chief Medical Officer

+1.1%1d on move date+1.3% vs SPY3d−1.8%5d−10.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more OCUL calls or request research access.

More OCUL calls Browse calls Request research access